NB 003 - Nysnobio
Alternative Names: NB-003 - NysnobioLatest Information Update: 15 Oct 2023
At a glance
- Originator NysnoBio
- Class Antiparkinsonians; Gene therapies
- Mechanism of Action Gene transference; Parkin protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Multiple system atrophy; Parkinson's disease
Most Recent Events
- 18 Sep 2023 NysnoBio plans to files an IND application for Multiple system atrophy and Parkinson's disease in the fourth quarter of 2025 (NysnoBio pipeline, September 2023)
- 18 Sep 2023 Early research in Multiple system atrophy in USA (Parenteral) (NysnoBio pipeline, September 2023)
- 18 Sep 2023 Early research in Parkinson's disease in USA (Parenteral) (NysnoBio pipeline, September 2023)